Piermont Capital Management’s Novavax NVAX Stock Holding History

Piermont Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-7,939	Closed	-$330K	–	266
2016 Q3	$330K	Buy	7,939 +668	+9%	+$86.2K	0.08%	245
2016 Q2	$1.06M	Buy	7,271 +3,541	+95%	+$406K	0.27%	139
2016 Q1	$385K	Buy	3,730 +137	+4%	+$14.7K	0.12%	189
2015 Q4	$603K	Buy	3,593 +649	+22%	+$99.9K	0.19%	123
2015 Q3	$416K	Hold	2,944	–	–	0.14%	169
2015 Q2	$656K	Buy	+2,944	New	+$517K	0.2%	118

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QIM

Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piermont Capital Management's NVAX Position: Q4 2016 in Review

Piermont Capital Management sold out of Novavax (NVAX) in Q4 2016, closing a stake of 7,939 shares — an estimated $330K sold.

Piermont Capital Management first reported a position in NVAX in Q2 2015 and held it in 6 quarters. The position peaked at $1.06M in Q2 2016. 142 funds tracked by Wall St. Rank hold NVAX as of Q4 2016.

Piermont Capital Management reported no remaining Novavax position as of Q4 2016 after selling out during the quarter.
Piermont Capital Management sold 7,939 Novavax shares in Q4 2016, an estimated $330K.
Piermont Capital Management first reported a position in Novavax in Q2 2015 and held it in 6 quarters.
Piermont Capital Management's Novavax position peaked at $1.06M in Q2 2016.
142 funds tracked by Wall St. Rank held Novavax as of Q4 2016.

Based on Piermont Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.